The expression and clinical significance of ERβ/ERα in ovarian cancer: can we predict the effectiveness of platinum plus taxane therapy?
Author:
Funder
the Ministry of Health of the Russian Federation
Publisher
Springer Science and Business Media LLC
Subject
General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11845-021-02842-6.pdf
Reference58 articles.
1. Saltel-Fulero A, Donnadieu A, Leman-Detours S, Cottu P (2016) New options in adjuvant endocrine therapy in breast cancer. Bull Cancer 103(1):104–112
2. Petit T (2019) Endocrine adjuvant treatment specific features for young breast cancer women. Bul Cancer 106(12s1):S24–S27
3. Daguenet E, Jmour O, Vallard A et al (2019) LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: ending the controversy for novel guidelines? Bull Cancer 106(4):342–353
4. Kjoe P, van der Wall E, Schagen SB (2021) Endocrine therapy with or without CDK4/6 inhibitors in women with hormone-receptor positive breast cancer: What do we know about the effects on cognition? Clin Breast Cancer
5. Mahadik N, Bhattacharya D, Padmanabhan A et al (2021) Targeting steroid hormone receptors for anti-cancer therapy—a review on small molecules and nanotherapeutic approaches. Wiley Interdiscip Rev Nanomed Nanobiotechnol e1755
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer;Cancer Letters;2023-10
2. Estrogen receptor α mediates alternariol-induced apoptosis and modulation of the invasiveness of ovarian cancer cells;Toxicology Letters;2023-09
3. Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL;Frontiers in Medicine;2023-06-29
4. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study;Cancers;2023-06-01
5. Tumor Cell Panel with Characterized Expression of PD-L1 for Preclinical Studies of Anticancer Drugs and Immune Checkpoint Inhibitors’ Interaction;Moscow University Chemistry Bulletin;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3